Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

Prior treatment

• Patients who have not undergone neoadjuvant chemotherapy,
• Patients with active central nervous system metastasis and carcinoma meningitis or patients who have been previously treated for brain metastases must be in a stable state in radiology,

Other illness

• Interval cytoreduction with more than 2.5 mm depth of residual disease,
• History of previous malignancy within five years prior to inclusion, that affects ovarian cancer treatment results, with the exception of carcinoma in situ, radically excised basal cell or squamous cell cancer of the skin, or synchronal endometrial carcinoma FIGO IA G1/2,
• Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML,
• Patients with antibacterial, antifungal, or antiviral infections requiring systemic treatment (administration of parenteral antibiotics),
• Active tuberculosis that is not controlled within 1 month of treatment,
• Patients diagnosed with a psychiatric disorder or substance abuse disorder that would interfere with your ability to cooperate with the trial,
• Patients with any contraindications to the use of cisplatin (i.e., hypersensitivity to cisplatin),
• Patients with a history of allogeneic tissue/solid organ transplantation or bone marrow transplantation or a history of double umbilical cord transplantation or,

Lab values

• History or current evidence of any condition, therapy, or laboratory abnormality that may confound the results of the study, or interfere with the patient's participation, in the opinion of the treating investigator.

Other

• Diagnosed with non-epithelial ovarian carcinoma or borderline ovarian tumor
• A life expectancy ≤3 months as clinically judged,

• Signed and written informed consent,
• Patients ≥18, <80 years old,
• Diagnosed with histologically confirmed FIGO stage III-IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer treated with three cycles of neoadjuvant chemotherapy,
• Treated with interval complete cytoreduction, or cytoreduction with no more than 2.5 mm depth of residual disease,
• A life expectancy > 3 months as clinically judged,
• Adequate organ function for cytoreductive surgery and HIPEC,
• Women who are medically unable to conceive or who are of childbearing potential, agree to follow contraceptive guidelines during treatment and,
• Patients can also consent to the provision of clinical information for secondary use, such as future biomedical research. However, in the future, subjects can participate in the main trial even if they do not intend to participate in sharing clinical information.